• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2

    BUSINESSWIRE

    ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test

    FIERCE BIOTECH

    Datroway Shows 5-Month Survival Gain Over Chemotherapy

    BUSINESSWIRE

    DS-3939 Shows Promising Activity in Advanced Solid Tumors

    BUSINESSWIRE

    ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off

    FIERCE PHARMA

    Enhertu+THP Yields 67% pCR in High-Risk HER2+ Breast Cancer

    BUSINESSWIRE

    Enhertu Cuts Recurrence or Death Risk by 53% in Ph3 Breast Trial

    BUSINESSWIRE

    ENHERTU® Preceded By THP Yields 67% Pathologic Response

    BUSINESSWIRE

    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer

    BUSINESSWIRE

    ESMO: Enhertu Wields 2-Fisted Power In Early Breast Cancer

    FIERCE PHARMA

    ESMO: Astrazeneca Data `Validate` Focus On In-House Adcs

    FIERCE BIOTECH

    Datroway`s Rilvegostomig Show Promise Result in Urothelial Cancer

    BUSINESSWIRE

    Daiichi Sankyo Advances Breast Cancer Care With Landmark Trials

    BUSINESSWIRE

    Daiichi Sankyo Establishes Third Research Institute In San Diego

    BUSINESSWIRE

    ENHERTU THP Combo BLA Accepted for High-Risk HER2+ Breast Cancer

    BUSINESSWIRE

    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer

    BUSINESSWIRE

    Az, Daiichi`s Enhertu Notches Another Win In Early Breast Cancer

    FIERCE PHARMA

    Enhertu And Pertuzumab Priority Review For Her2+ Breast Cancer

    BUSINESSWIRE

    ENHERTU + Pertuzumab Gets US Priority Review In 1L HER2+ Cancer

    BUSINESSWIRE

    Immuto Scientific Secures $8M Seed 2 Funding, Collaborates

    PHARMAWEB

    FDA Grants BTD To R-DXd For Platinum-Resistant Ovarian Cancers

    INDPHARMAPOST

    FDA Grants Breakthrough Tag to Raludotatug Deruxtecan in CDH6

    BUSINESSWIRE

    ENHERTU Type II Variation Validated in EU for HER2 Solid Tumors

    BUSINESSWIRE

    Daiichi, Merck Prepare for Swift Approval Filing

    FIERCE BIOTECH

    Daiichi Sankyo`s Ifinatamab Deruxtecan Shows Promising Response

    BUSINESSWIRE

    Daiichi Starts Development of Oral Triple Lipid-Lowering Combo

    BUSINESSWIRE

    HERTHENA-Breast04 Ph3 Starts for Patritumab Deruxtecan in Cancer

    BUSINESSWIRE

    Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation

    CONTRACTPHARMA

    Ifinatamab Deruxtecan Gets FDA BTD for ES-SCLC Patients

    BUSINESSWIRE

    Daiichi Sankyo Presents ADC Data, SCLC Updates at WCLC 2025

    BUSINESSWIRE

    Enhertu + Pertuzumab Get US BTD for HER2+ Breast Cancer

    BUSINESSWIRE

    Soriot plots move of AZ stock listing to US: The Times

    FIERCE PHARMA

    DATROWAY® approved in US for advanced EGFR-mutated lung cancer

    BUSINESSWIRE

    Datroway approved in US as first TROP2 Therapy for Lung Cancer

    BUSINESSWIRE

    IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Begins

    BUSINESSWIRE

    Daiichi Sankyo`s Vanflyta Approved in Canada

    HEALTH CANADA

    Enhertu Phase 3 Trial Begins for HER2+ Endometrial Cancer

    BUSINESSWIRE

    Enhertu+Pertuzumab Cuts Risk 44% in HER2+ Breast Ca Ph3

    BUSINESSWIRE

    Datroway Shows Promising Tumor Responses in Lung Cancer

    BUSINESSWIRE

    Enhertu Reduces Death Risk by 30% vs Ramucirumab Plus Paclitaxel

    BUSINESSWIRE

    Patritumab Deruxtecan BLA Withdrawn for EGFR-Mutated Lung Cancer

    BUSINESSWIRE

    Daiichi, Merck pull HER3-DXd filing at FDA

    REUTERS

    Endeavour Lung Program Launches Four Global Projects

    BUSINESSWIRE

    Daiichi Sankyo Transforms Cancer Treatment with Data at ASCO

    BUSINESSWIRE

    Malaysia`s IHH unit seeks $1.3 billion from Daiichi Sankyo

    REUTERS

    IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Begins

    BUSINESSWIRE

    AZ, Daiichi`s Enhertu tops SOC in early-stage breast cancer

    FIERCE PHARMA

    Enhertu + THP Boosts Complete Response in Breast Cancer Trial

    BUSINESSWIRE

    Enhertu Boosts Response in High-Risk HER2+ Breast Cancer

    BUSINESSWIRE

    Daiichi Sankyo reports solid launch for touted ADC Datroway

    FIERCE PHARMA

    Enhertu drives strong efficacy in first-line breast cancer

    BUSINESSWIRE

    Daiichi Sankyo honors its roots at DC cherry blossom fest

    FIERCE PHARMA

    Datroway® EU approval for metastatic HR+, HER2- breast cancer.

    BUSINESSWIRE

    Enhertu Approved in EU as First HER2 Therapy for HR+ Breast Cancer

    BUSINESSWIRE

    Daiichi Sankyo`s Datroway Receives Approval in Europe

    EMA

    ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer

    BUSINESSWIRE

    Daiichi taps Nosis to deliver RNA therapies beyond the liver

    BUSINESSWIRE

    EU Backs AstraZeneca-Daiichi’s Enhertu for Breast Cancer

    REUTERS

    CHMP Recommends ENHERTU For HER2 Low/Ultralow Metastatic Breast Cancer

    BUSINESSWIRE

    IHH Healthcare Seeks Damages from Daiichi Sankyo for Fortis Offer

    ACCESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.